For the fourth year running—and…
For the fourth year running—and the third in a row [...]
For the fourth year running—and the third in a row [...]
Vedanta Biosciences has “significantly reduced” its headcount to channel its [...]
Exelixis may only have one drug on the market right [...]
ImmunityBio has reported ongoing complete responses of up to 15 [...]
The long-awaited plan would leave much to Congress and calls [...]
The leaders of Chugai Pharmaceutical are tired of their company [...]
On this episode of “The Top Line,” we dig into [...]
New York’s attorney general has filed an insider trading lawsuit [...]
Many people who use these medications don’t want to stay [...]
Under CEO Richard Francis, Teva has long been looking to [...]